Two more C-suite hires at Xaira

Xaira Therapeutics Inc. continued building out its C-suite, naming Paulo Fontoura CMO and co-founder Hetu Kamisetty CTO. Fontoura was SVP neuroscience, immunology, ophthalmology, infectious and rare diseases at Roche (SIX:ROG; OTCQB:RHHBY). Xaira launched in April with a $1 billion venture round led by Arch Venture Partners and Foresite Capital and a license to a de novo computational antibody design technology from the lab of co-founder and 2024 Nobel Laureate David Baker.

CSO Robert Copeland will retire from  Accent Therapeutics Inc. on Dec. 31. Copeland, who co-founded the RNA epigenetics company in 2017, will be succeeded by VP of Biology Serena Silver...